Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

• Status: Recruiting
• Trial end date: 2022-12-31

Summary

This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.

• Phase: Phase 2

Details

• Lead Sponsor: Bukwang Pharmaceutical